Neuroscience Research Center, LLC



R.Drake9/2019-Ongoing: Principal InvestigatorTAURX THERAPEUTICS LTD. TRX-237-039RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, THREE-ARM, 9-MONTH, BRAIN IMAGING AND SAFETY AND EFFICACY STUDY OF LEUCO-METHYLTHIONINIUM BIS(HYDROMETHANESULFONATE) (LMTM) IN SUBJECTS WITH EARLY ALZHEIMER’S DISEASE.5/2019-Ongoing: Sub InvestigatorUCB BIOPHARMA SPRL EP0092A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFECIACY AND SAFETY OF PADSEVONIL AS ADJUNCTIVE TREATMENT OF FOCAL-ONSET SEIZURES IN ADULT SUBJECTS WITH DRUG-RESISTANT EPILEPSY3/2019-Ongoing: Principal InvestigatorOTSUKA PHARMACEUTICAL 405-201-00015AN OPEN LABEL,52 WEEK, MULTICENTER TRIAL EVALUATING THE LONG-TERM SAFETY AND TOLERABILITY OF CENTANAFADINE SUSTAINED-RELEASE TABLETS IN ADULTS WIT ATTENTION-DEFICIT/HYPERACTIVITY DISORDER.8/2017-2/2018: Principal InvestigatorF. HOFFMANN-LA ROCHE LTD BN29553A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY AND SAFETY STUDY OF CRENEZUMAB IN PATIENTS WITHPRODROMAL TO MILD ALZHEIMER’S DISEASE5/2017-8/2019: Principal InvestigatorALKERMES ALK8700-A302A PHASE 3 STUDY IN SUBJECTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS TO EVALUATE THE TOLERABILITY OF ALKS 8700 AND DIMETHYL FUMARATE2/2017-Ongoing: Principal InvestigatorEISAI E2609-G000-301A PLACEBO-CONTROLLED, DOUBLE-BLIND, PARALLEL-GROUP, 24-MONTH STUDY TO EVALUATE THE EFFICACY AND SAFETY OF E2609 IN SUBJECTS WITH EARLY ALZHEIMER’S DISEASE2/2017-4/2017: Principal InvestigatorVTV THERAPEUTICS LLC TTP488-301RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTI-CENTER REGISTRATION TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF TTP488 IN PATIENTS WITH MILD ALZHEIMER'S DISEASE RECEIVING ACETYLCHOLINESTERASE INHIBITORS AND/OR MEMANTIN11/2016-2017: Principal InvestigatorNOVARTIS COMB157G2301A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF OFATUMUMAB VERSUS TERIFLUNOMIDE IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS11/2016-3/2017: Sub InvestigatorALLERGAN CGP-MD-01PHASE 2/3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF MULTIPLE DOSING REGIMENS OF ORAL AGN-241689 IN EPISODIC MIGRAINE PREVENTION2/2016-7/2019: Principal InvestigatorSUVEN LIFE SCIENCES LTDA PHASE 2A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, 26-WEEK, PLACEBO-CONTROLLED STUDY OF 50 MG AND 100 MG OF SUVN-502 IN SUBJECTS WITH MODERATE ALZHEIMER’S DISEASE CURRENTLY TREATED WITH DONEPEZIL HYDROCHLORIDE AND MEMANTINE HYDROCHLORIDE1/2016-Ongoing: Principal InvestigatorEISAI E2609-G000-202A PLACEBO-CONTROLLED, DOUBLE-BLIND, PARALLEL-GROUP, RANDOMIZED, PROOF-OF-CONCEPT, DOSE-FINDING STUDY TO EVALUATE SAFETY, TOLERABILITY, AND EFFICACY OF E2609 IN SUBJECTS WITH MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMER’S DISEASE (PRODROMAL ALZHEIMER’S DISEASE) AND MILD TO MODERATE DEMENTIA DUE TO ALZHEIMER’S DISEASE (REVISED PER AMENDMENT 01)5/2016-Ongoing: Principal InvestigatorALKERMES ALK8700-A301A PHASE 3 OPEN LABEL STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ALKS 8700 IN ADULTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS2/2015-6/2017: Sub InvestigatorMERCK 8931-017A RANDOMIZED, PLACEBO CONTROLLED, PARALLEL-GROUP, DOUBLE BLIND EFFICACY AND SAFETY TRIAL OF MK-8931 IN SUBJECTS MILD TO MODERATE ALZHEIMER’S DISEASE11/2015- 6/2016: Sub InvestigatorMARINUSPROTOCOL 1042-0604 A FOLLOW-ON, TWO-YEAR OPEN-LABEL EXTENSION STUDY OF GANAXOLONE AS ADD-ON THERAPY IN ADULT PATIENTS WITH DRUG-RESISTANT PARTIAL-ONSET SEIZURES11/2014: Principal InvestigatorACORDA (DALF-PS-1016)A DOUBLE BLIND, PLACEBO CONTROLLED, PARALEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TWO DOSE STRENGHTS OF DALFAMPRIDINE EXTENDED RELEASE TABLETS FOR TREATMENT OF STABLE WALKING DEFICITS IN POST-ISCHEMIC STROKE (MILESTONE)12/2014: Principal InvestigatorBIOGEN 105MS401 (POP)PLEGRIDY (PEGINTERFERON β-1A) REAL WORLD EFFECTIVENESS AND SAFETY OBSERVATIONAL PROGRAM3/2014-1/2015: Principal InvestigatorBIOGEN 109MS404 (RESPOND)A MULTI-CENTER, OPEN-LABEL, 12 MONTH ONSERVATIONAL STUDY EVALUATING THE CLINICAL EFFECTIVENESS AND IMPACT ON PATIENT-REPORTED OUTCOMES OF ORAL TECFIDERA (DIMETHYL FUMARATE) DELAYED-RELEASE CAPSULES IN PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS AFTER SUBOPTIMAL RESPONSE TO GLATIRAMER ACETATE4/2014-8/2017: Principal InvestigatorBIOGEN 109MS401 (ESTEEM)A MULTICENTER, GLOBAL, OBSERVATIONAL STUDY TO COLLECT INFORMATION ON SAFETY AND TO DOCUMENT THE DRUG UTILIZATION OF TECFIDERA (DIMETHYL FUMARATE) WHEN USED IN A ROUTINE MEDICAL PRACTICE IN THE TREATMENT OF MULTIPLE SCLEROSIS (ESTEEM)4/2014-5/2018: Principal InvestigatorMERCK 8931-019A PHASE II/III RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP, DOUBLE BLIND CLINICAL TRIAL TO STUDY THE EFFICACY AND SAFETY OF MK 8931 IN SUBJECT WITH MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMER’S DISEASE (PRODROMAL AD)2/2014-6/2016: Sub InvestigatorMARINUS A MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL TO DETERMINE THE EFFICACY AND SAFETY OF GANAXOLONE AS ADJUNCTIVE THERAPY FOR ADULTS WITH DRUG-RESISTANT PARTIAL-ONSET SEIZURES FOLLOWED BY LONG-TERM OPEN-LABEL TREATMENT #1042-06032/2014-11/2014: Sub InvestigatorAVANIR PHARMACEUTICALS, INCA STUDY TO ASSESS THE SAFETY, TOLERABILITY AND EFFECTIVENESS OF NUEDEXTA (DEXTROMETHORPHAN 20MG/QUINIDINE 10MG) IN THE TREATMENT OF PSEUDOBULBAR AFFECT(PBA)3/2014-10/2014: Sub InvestigatorLABRYS BIOLOGICSA MULTICENTER, DOUBLE-BLIND, PLACEBO CONTROLLED PARALLEL-GROUP, STUDY COMPARING THE EFFICACY AND SAFETY OF TWO DOSES OF SUBCUTANEOUS LBR-101 WITH PLACEBO FOR THE PREVENTATIVE TREATMENT OF HIGH FREQUENCY EPISODIC MIGRAINE3/2014-10/2014: Sub InvestigatorLABRYS BIOLOGICSA MULTICENTER, DOUBLE-BLIND, DOUBLE DUMMY, PLACEBO CONTROLLED PARALLEL-GROUP, MULTI-DOSE STUDY COMPARING THE EFFICACY AND SAFETY OF TWO DOSES OF SUBCUTANEOUS LBR-101 WITH PLACEBO FOR THE PREVENTATIVE TREATMENT OF CHRONIC MIGRAINE8/2013-2/2014: Sub InvestigatorUCB N01358 A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, MULTICENTER, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BRIVARACETAM IN SUBJECTS (> 16 TO 80 YEARS OLD) WITH PARTIAL ONSET SEIZURES8/2103-2/2014: Sub InvestigatorUCB N01379AN OPEN-LABEL, MULTICENTER, FOLLOW-UP STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF BRIVARACETAM USED AS ADJUNCTIVE TREATMENT IN SUBJECTS AGED 16 YEARS OR OLDER WITH EPILEPSY8/2013-1/2015: Sub InvestigatorPFIZER A0081105 A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP, MULTICENTER TRIAL OF PREGABALIN AS ADJUNCTIVE THERAPY IN PEDIATRIC AND ADULT SUBJECTS WITH PRIMARY GENERALIZED TONIC CLONIC SEIZURE3/2013-6/2013: Sub InvestigatorALLERGAN GMA-BTX-CM-10-001 AN OPEN LABEL, MULTICENTER STUDY OF THE LONG TERM EFFICACY, SAFETY AND TOLERABILITY OF BOTOX (ONABOTULINUMTOXINA) FOR THE PROPHYLAXIS OF HEADACHES IN ADULT PATIENTS WITH CHRONIC MIGRAINE (THE COMPEL STUDY)6/2012-6/2015: Principal InvestigatorNOVARTIS CFTY720DUS09A 12-MONTH, PROSPECTIVE, RANDOMIZED, ACTIVE-CONTROLLED, OPEN-LABEL STUDY TO EVALUATE THE PATIENT RETENTION OF FINGOLIMOD VS APPROVED FIRST LINE DISEASE MODIFYING THERAPIES IN ADULTS WHO ARE IN EARLY STAGES OF TREATMENT FOR RELAPSING REMITTING MULTIPLE SCLEROSIS (PREFERMS)5/2012-6/2013: Sub InvestigatorUCB SP0980 (VIMPAT)A PROSPECTIVE, MULTINATIONAL, OPEN-LABEL, SINGLE-ARM, EXPLORATORY STUDY TO EVALUATE THE TOLERABLITY AND EFFICACY OF LACOSAMIDE WHEN ADDED TO LEVETIRACETAM WITH WITHDRAWAL OF THE CONCOMITANT SODIUM CHANNEL BLOCKING ANTIEPILEPTIC DRUG IN SUBJECTS WITH UNCONTROLLED PARTIAL-ONSET SEIZURES 11/2010-10/2011: Sub InvestigatorNOVARTIS CFTY720DUS01 A 6 MONTH, RANDOMIZED, ACTIVE COMPARATOR, OPEN-LABEL, MULTI-CENTER, STUDY TO EVALUATE PATIENT OUTCOMES, SAFETY AND TOLERABILITY OF FINGOLIMOD/DAY IN PATIENTS WITH RELAPSING FORMS OF MULTIPLE SCLEROSIS WHO ARE CANDIDATES FOR MS THERAPY CHANGE FROM PREVIOUS DISEASE MODIFYING THERAPY (EPOC) ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download